Status:
COMPLETED
A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies
Lead Sponsor:
AEterna Zentaris
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase I study which will analyze any food-drug effects as well as QTc effects of perifosine. Safety and efficacy will also be evaluated. Patients who complete the first 24 days on single ag...
Detailed Description
Exclusion Criteria: 1. Patients with prior exposure to perifosine. 2. Patients receiving any other chemotherapy, targeted agents, investigational agents or devices within four weeks (28 days) or 5 ha...
Eligibility Criteria
Inclusion
- Patients with advanced malignancies
- Patients with adequate organ and marrow function
Exclusion
- Patients previously treated with perifosine
- Patients receiving any other chemotherapy, targeted agents, investigational agents or devices within four weeks (28 days) prior to Day 1 of study treatment
Key Trial Info
Start Date :
January 24 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 4 2013
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01224730
Start Date
January 24 2012
End Date
November 4 2013
Last Update
March 14 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dallas, Texas, United States, 75230
2
Houston, Texas, United States, 77030